Cargando…

Novel ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo

Detalles Bibliográficos
Autores principales:	Bullen, C. Korin, Laird, Gregory M., Durand, Christine M., Siliciano, Janet D., Siliciano, Robert F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981911/ https://www.ncbi.nlm.nih.gov/pubmed/24658076 http://dx.doi.org/10.1038/nm.3489

Ejemplares similares

Inconsistent reversal of HIV-1 latency ex vivo by antigens of HIV-1, CMV, and other infectious agents
por: Vollbrecht, Thomas, et al.
Publicado: (2020)

Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency
por: Zerbato, Jennifer M., et al.
Publicado: (2021)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

Rapid Quantification of the Latent Reservoir for HIV-1 Using a Viral Outgrowth Assay
por: Laird, Gregory M., et al.
Publicado: (2013)

Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo
por: Falcinelli, Shane D., et al.
Publicado: (2022)

Targeting of HIV-1 Antigens for Rapid Intracellular Degradation Enhances Cytotoxic T Lymphocyte (CTL) Recognition and the Induction of De Novo CTL Responses In Vivo After Immunization
por: Tobery, Timothy W., et al.
Publicado: (1997)

Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo
por: Spivak, Adam M., et al.
Publicado: (2016)

PD-1 blockade potentiates HIV latency reversal ex vivo in CD4(+) T cells from ART-suppressed individuals
por: Fromentin, Rémi, et al.
Publicado: (2019)

Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions
por: Hill, Alison L., et al.
Publicado: (2016)

Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir
por: Wang, Zheng, et al.
Publicado: (2018)

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression
por: Darcis, Gilles, et al.
Publicado: (2015)

Latency reversal plus natural killer cells diminish HIV reservoir in vivo
por: Kim, Jocelyn T., et al.
Publicado: (2022)

Limits on Replenishment of the Resting CD4(+) T Cell Reservoir for HIV in Patients on HAART
por: Sedaghat, Ahmad R, et al.
Publicado: (2007)

Efforts to eliminate the latent reservoir in resting CD4+ T cells: strategies for curing HIV-1 infection
por: Ho, Ya-Chi, et al.
Publicado: (2015)

HIV replication and evolution in patients on highly active antiretroviral therapy
por: Siliciano, Robert F
Publicado: (2006)

Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo
por: Nixon, Christopher C., et al.
Publicado: (2020)

NSC95397 is a Novel HIV Latency Reversing Agent
por: Nichols Doyle, Randilea, et al.
Publicado: (2023)

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation
por: Gunst, Jesper D, et al.
Publicado: (2019)

HIV Prevention and Treatment Fields Join Forces
por: Deeks, Steven G., et al.
Publicado: (2014)

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
por: Marsden, Matthew D., et al.
Publicado: (2018)

HIV latency reversing agents act through Tat post translational modifications
por: Khoury, Georges, et al.
Publicado: (2018)

HIV latency and integration site placement in five cell-based models
por: Sherrill-Mix, Scott, et al.
Publicado: (2013)

HIV-1 Latency and Latency Reversal: Does Subtype Matter?
por: Sarabia, Indra, et al.
Publicado: (2019)

Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
por: Gupta, Vipul, et al.
Publicado: (2018)

HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function
por: Garrido, Carolina, et al.
Publicado: (2016)

Multiplexed Imaging Strategy to Distinguish Indeterminant Biliary Strictures: An Ex Vivo Study
por: Sturm, MB, et al.
Publicado: (2020)

New Concepts in Therapeutic Manipulation of HIV-1 Transcription and Latency: Latency Reversal versus Latency Prevention
por: Lewis, Catherine A., et al.
Publicado: (2023)

Measuring the latent reservoir for HIV-1: Quantification bias in near full-length genome sequencing methods
por: White, Jennifer A., et al.
Publicado: (2022)

A Quantitative Basis for Antiretroviral Therapy for HIV-1 Infection
por: Jilek, Benjamin L., et al.
Publicado: (2012)

Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents
por: Sorensen, Eric S., et al.
Publicado: (2020)

Designing and Interpreting Limiting Dilution Assays: General Principles and Applications to the Latent Reservoir for Human Immunodeficiency Virus-1
por: Rosenbloom, Daniel I. S., et al.
Publicado: (2015)

Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins?
por: Vignesh, Ramachandran, et al.
Publicado: (2017)

New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models
por: Bricker, Katherine M., et al.
Publicado: (2021)

Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells
por: Boucau, Julie, et al.
Publicado: (2020)

Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA
por: Taylor, Jared P., et al.
Publicado: (2020)

Discovering the Mechanisms of Oleodaphnone as a Potential HIV Latency-Reversing Agent by Transcriptome Profiling
por: Li, Shifei, et al.
Publicado: (2023)

Epigenetic Regulation of HIV-1 Sense and Antisense Transcription in Response to Latency-Reversing Agents
por: Li, Rui, et al.
Publicado: (2023)

The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function
por: Clutton, G., et al.
Publicado: (2016)

Latency Reversing Agents: Kick and Kill of HTLV-1?
por: Schnell, Annika P., et al.
Publicado: (2021)

Impact of latency‐reversing agents on human macrophage physiology
por: Hany, Laurent, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dljmgeqn8qt0slra9q3vcca532